The Relationship of Prolactin and Inflammatory Markers With Parkinson's Disease Severity: Clinical and Biochemical Evaluation
Trial Snapshot
- Phase
- Not Applicable
- Status
- Enrolling By Invitation
- Sponsor
- Enrollment
- 300
- Locations
- 1
- Primary Endpoint
- Systemic inflammatory markers
Study Overview
Brief Summary
This cross-sectional observational study aims to evaluate the relationship between serum prolactin levels, peripheral inflammatory markers (NLR, PLR, SII, CRP), and disease severity in patients with Parkinson's disease (PD). A total of at least 300 patients diagnosed with idiopathic PD will be included. Disease severity will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) and the Modified Hoehn-Yahr staging system. Serum and salivary prolactin levels will be measured using ELISA, while inflammatory markers will be calculated from routine blood tests. The study seeks to clarify whether prolactin and systemic inflammation indicators may serve as non-invasive biomarkers for disease progression and prognosis in PD, with particular emphasis on postmenopausal women.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 18 years
- •Diagnosis of idiopathic Parkinson's disease confirmed by a neurologist
- •Both male and postmenopausal female patients
- •Patients able to provide informed consent
- •Clinically stable enough to undergo blood and saliva sampling, as well as neurological assessment
Exclusion Criteria
- •Premenopausal female patients
- •Patients with secondary or atypical parkinsonism (e.g., drug-induced, vascular, atypical parkinsonian syndromes)
- •Known endocrine disorders affecting prolactin levels (e.g., prolactinoma, pituitary adenoma, hypothyroidism)
- •Use of medications known to alter prolactin secretion (e.g., antipsychotics, dopamine antagonists, estrogen therapy)
- •History of other neurodegenerative diseases (e.g., Alzheimer's, Huntington's)
- •Presence of active infection, chronic inflammatory disease, or malignancy
- •Severe renal, hepatic, or cardiac failure
- •Inability to provide informed consent
Outcomes
Primary Outcomes
Systemic inflammatory markers
Time Frame: 1 year later
NLR, PLR, SII, CRP
Prolactin Level
Time Frame: 1 year later
Serum prolactine levels
Secondary Outcomes
No secondary outcomes reported
Investigators
Hüseyin Avni Eroğlu
Assoc. Prof.
Çanakkale Onsekiz Mart University